The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognosis and clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma.
 
Mahmoud M.G. Yousef
No Relationships to Disclose
 
Abdelrahman M.G. Yousef
No Relationships to Disclose
 
Mark W. Hurd
No Relationships to Disclose
 
Ethan B. Ludmir
Employment - Alaunos Therapeutics (I)
 
Eugene Jon Koay
No Relationships to Disclose
 
Rebecca A Snyder
No Relationships to Disclose
 
Huamin Wang
No Relationships to Disclose
 
Ching-Wei D. Tzeng
Honoraria - PanTher Therapeutics
Research Funding - Sirtex Medical (Inst)
 
Anirban Maitra
Consulting or Advisory Role - Freenome; Tezcat Biosciences
Patents, Royalties, Other Intellectual Property - Johns Hopkins University has licensed a patent related to pancreatic cancer to Thrive Earlier Detection. I have 1.8% contribution on that patent.; PCT/US2017/066851 (Inst)
 
Shubham Pant
Consulting or Advisory Role - AskGene Pharma; Boehringer Ingelheim; Ipsen; Janssen; Novartis; Zymeworks
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
James C. Yao
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Chiasma; Crinetics Pharmaceuticals; Hutchison MediPharma; Ipsen
Research Funding - Advanced Accelerator Applications; Novartis
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences
Research Funding - BostonGene; Celsius Therapeutics; Celsius Therapeutics
 
Dan Zhao
Consulting or Advisory Role - Affinit-T
Research Funding - CARsgen Therapeutics (Inst); Mirati Therapeutics (Inst)